Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2008 2
2010 1
2013 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
[Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)].
Ray-Coquard I, Kassab-Chahmi D, Casadevall N, Chastagner P, Marchal C, Marec-Bérard P, Misset JL; Standards, Options et Recommandations (SOR); Institut National du Cancer; Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC); Ligue contre le Cancer pour la Vie; Fédération Hospitalière de France; Fédération Nationale de Cancérologiedes Centres Hospitaliers Regionaux et Universitaires (FNCHRU); Fédération Française de Cancérologie; Union Nationale Hospitalière Privée de Cancérologie (UNHPC). Ray-Coquard I, et al. Bull Cancer. 2008 Apr;95(4):433-41. doi: 10.1684/bdc.2008.0635. Bull Cancer. 2008. PMID: 18495573 Free article. Review. French.
[Standards, Options: Recommendations for the management of patients with epithelial ovarian cancer. Medical front-line treatment (summary report, update 2008)].
Fédération nationale des centres de lutte contre le cancer (FNCLCC). Fédération nationale des centres de lutte contre le cancer (FNCLCC). Gynecol Obstet Fertil. 2008 Jun;36(6):684-700. doi: 10.1016/j.gyobfe.2008.04.009. Epub 2008 Jun 9. Gynecol Obstet Fertil. 2008. PMID: 18539509 Review. French.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients.
Ray-Coquard I, Weber B, Lotz JP, Tournigand C, Provencal J, Mayeur D, Treilleux I, Paraiso D, Duvillard P, Pujade-Lauraine E; GINECO group. Ray-Coquard I, et al. Gynecol Oncol. 2010 Oct;119(1):53-9. doi: 10.1016/j.ygyno.2010.05.023. Epub 2010 Jun 30. Gynecol Oncol. 2010. PMID: 20580063